Cetuximab can specifically bind to EGF receptors expressed on the surface of normal cells and a variety of cancer cells, and competitively block EGF and other ligands, such as α Transforming growth factor (TGF- α） A combination of. This product is an IgG1 monoclonal antibody against EGF receptor. After specific combination, it blocks the signal transduction pathway in cells by inhibiting the tyrosine kinase (TK) bound to EGF receptor, thereby inhibiting the proliferation of cancer cells, inducing apoptosis of cancer cells, and reducing the production of matrix metalloproteinases and vascular endothelial growth factor.

Cetuximab is mainly an anti-tumor targeting drug, which is a monoclonal antibody against epidermal growth factor receptor. It can inhibit the vascular growth factor secreted by tumor cells and reduce the neogenesis and metastasis of tumor blood vessels.

When cetuximab is used, there may be hypersensitivity reactions, such as fever, chills, nausea, rash, dyspnea, etc. Therefore, antihistamine drugs must be used before medication.

西妥昔單抗主要是一種抗腫瘤的靶向藥物，是針對表皮生長因子受體的單克隆抗體。抑制腫瘤細(xì)胞分泌的血管生長因子，減少腫瘤血管的新生和轉(zhuǎn)移。

西妥昔單抗應(yīng)用時有發(fā)生超敏反應(yīng)的可能，例如發(fā)熱，寒戰(zhàn)，皮疹，呼吸困難等。因此在用藥之前一定要應(yīng)用抗組胺的藥物治療。

艾美捷西妥昔單抗Cetuximab：

中文名稱：西妥昔單抗（抗EGFR）

英文名字：Cetuximab (anti-EGFR)

編號：MBS5759550

規(guī)格：1mg /5mg/10mg/25mg/50mg/5x50mg    

保存建議：在-20℃下儲存3年粉末；-80℃，在溶劑中2年

艾美捷西妥昔單抗Cetuximab相關(guān)研究：

抗碳酸酐酶VI（CA6）MBS20003406的多克隆抗體

抗脂肪酸轉(zhuǎn)運(yùn)蛋白5（FATP5）MBS20003405的生-物-素連接抗體

淋巴細(xì)胞抗原9（LY9）生-物-素連接抗體MBS20003404

生-物-素連接的抗消化因子2抗體（GKN2）MBS20003403

抗細(xì)胞周期蛋白D1（CCND1）MBS20003402的多克隆抗體